GLP-1 stands for glucagon-like peptide-1, a hormone your gut releases after eating that prompts insulin, slows stomach emptying, and dials down appetite. Drugs that mimic it are the reason weight medicine changed so fast over the past decade. Once you understand that single hormone, most of the vocabulary in this field falls into place.<\/p>\n
This glossary covers the terms you meet when starting or researching a GLP-1 program, arranged roughly A to Z within five groups. Some are biology, some are drug names, and some belong to the clinic or the pharmacy. Where a term carries a common misconception, the entry clears it up, because the wrong mental model causes more dosing errors than any single fact.<\/p>\n
At TrimRx, we believe that knowing the language is part of knowing your options. If a GLP-1 program might fit your goals, you can take the free assessment quiz and have a clinician review your situation.<\/p>\n
At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.<\/p>\n
These foundational terms explain how GLP-1 drugs work.<\/strong> Understand these and the drug names later make sense, because every one of them acts on the same machinery.<\/p>\n Quick Answer: GLP-1 stands for glucagon-like peptide-1, a gut hormone that lowers blood sugar and reduces appetite. It is the foundation of modern weight medications.<\/p>\n A1C<\/strong>. A blood test reflecting average blood sugar over about three months. GLP-1 drugs usually lower it, which is why it tracks diabetes control.<\/p>\n Agonist<\/strong>. A molecule that activates a receptor. GLP-1 drugs are receptor agonists, meaning they switch on the GLP-1 receptor the way the natural hormone does.<\/p>\n Appetite suppression<\/strong>. A main effect of GLP-1 drugs. They act on brain centers that regulate hunger and fullness, so you feel satisfied with less food.<\/p>\n Beta cells<\/strong>. The pancreas cells that make insulin. GLP-1 prompts them to release insulin, but only when blood sugar is high, which limits the risk of lows.<\/p>\n Glucagon-like peptide-1 (GLP-1)<\/strong>. The gut hormone at the center of it all. Released after meals, it raises insulin, slows digestion, and reduces appetite.<\/p>\n GIP<\/strong>. Glucose-dependent insulinotropic polypeptide, a second gut hormone. Tirzepatide targets GIP and GLP-1 together, which is why it is called a dual agonist.<\/p>\n Incretin<\/strong>. The class of gut hormones, including GLP-1 and GIP, that boost insulin after eating. GLP-1 drugs are sometimes called incretin mimetics.<\/p>\n Insulin<\/strong>. The hormone that moves sugar from blood into cells. GLP-1 drugs increase insulin release in a glucose-dependent way.<\/p>\n Receptor<\/strong>. The docking site on a cell that a hormone or drug binds. GLP-1 drugs bind the GLP-1 receptor to produce their effects.<\/p>\n Satiety<\/strong>. The feeling of fullness. GLP-1 drugs increase satiety both by slowing the stomach and by acting on the brain.<\/p>\n Gastric emptying<\/strong>. The rate at which food leaves the stomach. GLP-1 drugs slow it, which extends fullness and is one reason early nausea happens.<\/p>\n Glucose-dependent<\/strong>. A safety feature of GLP-1 action. The drugs boost insulin mainly when blood sugar is elevated, so they rarely cause dangerous lows on their own.<\/p>\n Pancreas<\/strong>. The organ that makes insulin and glucagon. GLP-1 acts here to fine-tune blood sugar after meals.<\/p>\n These are the GLP-1 and dual-agonist medications by name, with their brand and compounded forms.<\/strong> Registered marks appear on first use.<\/p>\n Compounded semaglutide<\/strong>. Semaglutide prepared by a licensed compounding pharmacy, dispensed in vials with personalized dosing. Same active molecule as the brand, with no equivalency claim implied.<\/p>\n Compounded tirzepatide<\/strong>. Tirzepatide prepared by a compounding pharmacy, also dispensed in vials. Like compounded semaglutide, it is available through 503A pharmacies with personalization.<\/p>\n Dulaglutide<\/strong>. A weekly GLP-1 agonist, the active drug in Trulicity\u00ae.<\/p>\n Liraglutide<\/strong>. A daily GLP-1 agonist, the molecule in Saxenda\u00ae for weight and Victoza\u00ae for diabetes.<\/p>\n Mounjaro\u00ae<\/strong>. The brand tirzepatide product approved for type 2 diabetes.<\/p>\n Oral semaglutide<\/strong>. A pill form of semaglutide. Rybelsus\u00ae was the first, and an oral version of Wegovy\u00ae gained approval, making higher-dose oral semaglutide available in 2026.<\/p>\n Ozempic\u00ae<\/strong>. The brand semaglutide product approved for type 2 diabetes, widely used off-label for weight.<\/p>\n Rybelsus\u00ae<\/strong>. The original oral semaglutide tablet, approved for type 2 diabetes.<\/p>\n Semaglutide<\/strong>. A long-acting GLP-1 analog, studied in the STEP trials (Wilding 2021, NEJM). The basis for Ozempic\u00ae, Wegovy\u00ae, and Rybelsus\u00ae.<\/p>\n Tirzepatide<\/strong>. A dual GIP and GLP-1 agonist, studied in SURMOUNT-1 (Jastreboff 2022, NEJM). Sometimes called a twincretin.<\/p>\n Trulicity\u00ae<\/strong>. The brand dulaglutide product for type 2 diabetes.<\/p>\n Wegovy\u00ae<\/strong>. The brand semaglutide product approved specifically for weight management, including the oral form approved in 2026.<\/p>\n Zepbound\u00ae<\/strong>. The brand tirzepatide product approved for weight management.<\/p>\n These terms cover how the drug gets into you and how doses are described.<\/strong> They come up the day you start.<\/p>\n Beyond-use date<\/strong>. The date after which a compounded GLP-1 should not be used, set by the pharmacy.<\/p>\n Concentration<\/strong>. The drug per milliliter in a vial, written mg\/mL. It sets how many syringe units a dose takes.<\/p>\n Half-life<\/strong>. The time for half a dose to clear. Semaglutide’s roughly week-long half-life is why it doses once weekly.<\/p>\n Maintenance dose<\/strong>. The steady dose held after titration once appetite control is reached. Many people stop below the maximum.<\/p>\n Maximum dose<\/strong>. The top of the approved dose range, 2.4 mg weekly for semaglutide in weight management and up to 15 mg weekly for tirzepatide.<\/p>\n Prefilled pen<\/strong>. A single-use or multi-use injector preloaded with brand drug, dosed by clicks rather than syringe units.<\/p>\n Starting dose<\/strong>. The low opening dose, 0.25 mg weekly for semaglutide and 2.5 mg weekly for tirzepatide, used to limit side effects.<\/p>\n Subcutaneous injection<\/strong>. An injection into the fat under the skin, the standard route for injectable GLP-1 drugs.<\/p>\n Titration<\/strong>. The gradual dose increase, usually monthly, that lets your body adjust to the medication.<\/p>\n U-100 syringe<\/strong>. An insulin syringe scaled so 100 units equals 1 mL, used to draw compounded GLP-1 doses.<\/p>\n Units<\/strong>. The marks on an insulin syringe. Your dosing card converts your milligram dose into units.<\/p>\n Vial<\/strong>. The glass container holding compounded GLP-1, used for repeated weekly draws.<\/p>\n Dose escalation<\/strong>. Another name for titration, the planned series of increases that move you from the starting dose toward your target.<\/p>\n Injection site rotation<\/strong>. The practice of moving where you inject each week, usually among the abdomen, thigh, and upper arm, to reduce skin irritation.<\/p>\n Missed dose window<\/strong>. The period in which a late weekly dose can still be taken safely. For semaglutide it is generally several days, after which you skip and resume on schedule.<\/p>\n These come up in your bloodwork and your provider’s notes.<\/strong> Knowing them helps you read your own results.<\/p>\n BMI<\/strong>. Body mass index, weight relative to height. It often sets eligibility for weight medications, though it is an imperfect measure.<\/p>\n Comorbidity<\/strong>. A second condition alongside obesity, such as high blood pressure, that can affect treatment decisions.<\/p>\n eGFR<\/strong>. Estimated glomerular filtration rate, a kidney function measure. The FLOW trial (Perkovic 2024, NEJM) showed semaglutide benefits in kidney disease.<\/p>\n Fasting glucose<\/strong>. Blood sugar measured after not eating, a basic metabolic check.<\/p>\n GI side effects<\/strong>. Gastrointestinal effects like nausea, the most common GLP-1 side effects, usually worst right after a dose increase.<\/p>\n Lipid panel<\/strong>. A blood test of cholesterol and triglycerides, often tracked during treatment.<\/p>\n MACE<\/strong>. Major adverse cardiovascular events. The SELECT trial (Lincoff 2023, NEJM) showed semaglutide cut these in people with overweight and heart disease.<\/p>\n Plateau<\/strong>. A stall in weight loss after initial progress, common and usually addressed by reviewing dose, diet, and activity.<\/p>\n SURMOUNT<\/strong>. The trial program for tirzepatide in weight management.<\/p>\n STEP<\/strong>. The trial program for semaglutide in weight management.<\/p>\n Thyroid C-cell<\/strong>. A cell type relevant to a boxed warning on GLP-1 drugs based on rodent studies, prompting caution in people with certain thyroid cancer histories.<\/p>\n Pancreatitis<\/strong>. Inflammation of the pancreas, a rare but serious risk providers screen for before and during GLP-1 treatment.<\/p>\n Lean mass<\/strong>. Muscle and other non-fat tissue. Rapid weight loss can reduce lean mass, which is why protein intake and activity matter on GLP-1 drugs.<\/p>\n Key Takeaway: Key drug names to know: semaglutide (Ozempic\u00ae, Wegovy\u00ae, Rybelsus\u00ae), tirzepatide (Mounjaro\u00ae, Zepbound\u00ae), and liraglutide (Saxenda\u00ae).<\/p>\n These terms describe how people actually obtain GLP-1 drugs and what shapes the price.<\/strong> They matter in 2026 more than ever.<\/p>\n 503A pharmacy<\/strong>. A state-licensed compounding pharmacy that prepares personalized medications from a prescription.<\/p>\n 503B outsourcing facility<\/strong>. A federally registered compounder making larger batches under stricter standards.<\/p>\n Compounding<\/strong>. Preparing a customized medication for a patient, the route for personalized GLP-1 dosing.<\/p>\n Coverage<\/strong>. Whether insurance pays for a drug. GLP-1 coverage for weight remains uneven across plans.<\/p>\n LegitScript certification<\/strong>. Third-party verification that a telehealth or pharmacy operator meets legal and safety standards.<\/p>\n Off-label<\/strong>. Using an approved drug for an unapproved purpose, such as Ozempic\u00ae for weight, which is legal.<\/p>\n Prior authorization<\/strong>. An insurer’s requirement that a provider justify a prescription before it is covered.<\/p>\n Shortage<\/strong>. A supply gap. GLP-1 shortages drove much of the compounding demand, and supply status shifts over time.<\/p>\n TrumpRx<\/strong>. A 2026 pricing program that made certain brand GLP-1 drugs available at set prices, changing the cost picture.<\/p>\n Telehealth<\/strong>. Remote medical care by video or messaging, the main channel for compounded GLP-1 access.<\/p>\n The terms link together in a clear sequence once you start.<\/strong> First comes eligibility, where BMI and any comorbidity decide whether a medication fits. Then comes the choice of molecule, semaglutide or tirzepatide, brand or compounded. Most people researching cost in 2026 weigh brand pricing shaped by TrumpRx against compounded options from a 503A pharmacy.<\/p>\n Next is titration. You start low, 0.25 mg weekly for semaglutide or 2.5 mg weekly for tirzepatide, and step up about monthly. Each increase is when GI side effects peak, so the schedule trades patience for tolerability. Your dosing card converts your milligram dose into syringe units based on the vial’s concentration, which is the single most error-prone step.<\/p>\n Once you reach a maintenance dose that controls appetite, you settle into a routine of weekly injections, site rotation, and tracking. Labs like A1C, fasting glucose, and a lipid panel show how your metabolism responds. The big trials in the background, STEP for semaglutide and SURMOUNT for tirzepatide, plus SELECT for heart outcomes and FLOW for kidney outcomes, are the evidence your provider leans on when explaining what to expect.<\/p>\n Knowing the words in advance means none of this feels like a foreign language when it happens. You walk into the consult already fluent.<\/p>\n Use it as a reference, not a test.<\/strong> When your labs, your provider, or an article uses a term you are unsure of, look it up here. The most valuable terms are the ones that prevent errors, like the difference between a vial’s total milligrams and your weekly dose. A TrimRX clinician walks you through the terms that apply to your specific plan, which is what the free assessment quiz starts.<\/p>\n GLP-1 means glucagon-like peptide-1, a hormone your gut releases after meals. It prompts insulin release, slows stomach emptying, and reduces appetite. GLP-1 medications copy this hormone, which is why they help with both blood sugar and weight.<\/p>\n Semaglutide activates the GLP-1 receptor only. Tirzepatide activates both GLP-1 and GIP receptors, which is why it is called a dual agonist or twincretin. In trials, tirzepatide produced larger average weight loss, though individual results vary and side-effect profiles overlap.<\/p>\n Both contain semaglutide, but they are approved for different uses and dosed differently. Ozempic\u00ae is approved for type 2 diabetes, Wegovy\u00ae for weight management. An oral form of Wegovy\u00ae was approved in 2026, adding a pill option at weight-management doses.<\/p>\n Titration is the slow, usually monthly, increase in dose that lets your body adjust. Both semaglutide and tirzepatide start at a low dose and step up over weeks. This schedule reduces gastrointestinal side effects, which are worst right after each increase.<\/p>\n TrumpRx is a 2026 pricing program that made certain brand GLP-1 drugs available at set prices. It changed the cost comparison between brand and compounded options for some patients, though coverage and eligibility still vary by situation.<\/p>\n Compounded semaglutide uses the same active molecule as Wegovy\u00ae, prepared by a licensed compounding pharmacy rather than the brand maker. It allows personalized dosing in vials. No equivalency claim is made between compounded and brand products, and a clinician explains the differences during onboarding.<\/p>\n Disclaimer:<\/strong> This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.<\/p>\n","protected":false},"excerpt":{"rendered":" Introduction GLP-1 stands for glucagon-like peptide-1, a hormone your gut releases after eating that prompts insulin, slows stomach emptying, and dials down appetite. Drugs…<\/p>\n","protected":false},"author":11,"featured_media":106107,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","footnotes":"","_flyrank_wpseo_metadesc":""},"categories":[14],"tags":[],"class_list":["post-106108","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-zepbound"],"_links":{"self":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/106108","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/comments?post=106108"}],"version-history":[{"count":1,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/106108\/revisions"}],"predecessor-version":[{"id":107925,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/106108\/revisions\/107925"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media\/106107"}],"wp:attachment":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media?parent=106108"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/categories?post=106108"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/tags?post=106108"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Group 2: The Named Drugs<\/h2>\n
Group 3: Dosing and Delivery<\/h2>\n
Group 4: Clinical and Lab Terms<\/h2>\n
Group 5: The Access and Cost Side<\/h2>\n
How Do These Terms Connect in a Real GLP-1 Journey?<\/h2>\n
How to Use This Glossary<\/h2>\n
FAQ<\/h2>\n
What Does GLP-1 Actually Stand For?<\/h3>\n
What Is the Difference Between Semaglutide and Tirzepatide?<\/h3>\n
Are Ozempic\u00ae and Wegovy\u00ae the Same Drug?<\/h3>\n
What Does Titration Mean for GLP-1 Drugs?<\/h3>\n
What Is TrumpRx in the Context of GLP-1 Pricing?<\/h3>\n
Is Compounded Semaglutide the Same as Wegovy?<\/h3>\n